stockrow
Friday 6 November 2026
Export CTXR’s income statement to Excel — free account
Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
- EPS
- +57.5%
- Free cash flow
- −60.5%
Quarter to June 2026, against a year earlier
0.55
0.01
−1.79%
Follow CTXR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
0.00 | 0.00 | 0.00 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(1.81) | (15.49) | (1.29) | — | |
P/B ratio |
0.21 | 0.29 | 0.18 | — | |
Price to Tangible BV |
0.24 | 0.34 | 0.20 | — | |
EV/Sales |
0.00 | 0.00 | 0.00 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(0.15) | (0.50) | (0.27) | — | |
EV/FCF |
(0.15) | (0.50) | (0.27) | — | |
Quick Ratio |
0.34 | 0.10 | 0.31 | 0.09 | |
Current Ratio |
0.84 | 0.58 | 0.99 | 0.62 | |
Net Debt/EBITDA |
1.08 | 0.15 | 0.91 | 0.51 | |
Debt/Assets |
4.51% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.08 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 0.06 | 1.58 | 1.49 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(50.63) | (975.60) | (58.00) | (88.35) | |
Research and Development Expense of Revenue |
70.55% | 97.97% | 40.56% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
666.74% | 1,810.08% | 253.57% | 0.00% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
255.10% | 227.21% | 108.52% | 0.00% | |
Graham Net Nets |
(1.47) | (1.58) | (0.54) | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(355.55%) | (288.14%) | (373.50%) | — | |
Free Cash Flow Yield |
(222.11%) | (156.94%) | (207.82%) | — | |
Revenue per Share |
0.06 | 0.07 | 0.18 | 0.00 | |
Operating CF per Share |
(0.33) | (0.06) | (0.61) | (1.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.33) | (0.06) | (0.61) | (1.07) | |
Cash per Share |
0.65 | 0.21 | 0.36 | 0.38 | |
Shareholders Equity per Share |
2.90 | 3.09 | 4.35 | 7.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.90 | 3.09 | 4.35 | 7.01 | |
Free Cash Flow |
(8.68) | (1.30) | (13.01) | (11.88) | |
Working Capital |
(8.32) | (23.33) | (0.26) | (16.98) | |
Net Current Asset Value |
(23.02) | (31.77) | (8.98) | (25.48) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Payables |
9.07 | 9.41 | 9.19 | 9.31 | |
Average Inventory |
19.92 | 19.00 | 18.51 | 15.28 | |
Average Assets |
134.97 | 127.01 | 130.55 | 123.79 | |
Average Common Equity |
71.73 | 66.33 | 81.19 | 75.81 |
Columns are period end dates · fundamentals updated 26 Oct 2026